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Abstract 
The thymus contributes naïve, self MHC reactive, self tolerant T-cells to the 
peripheral immune system throughout life, albeit with a log-linear decline with age. 
Quantification of thymic function is clinically relevant in the setting of 
lymphoablation, but a phenotypic marker distinguishing recent thymic emigrants from 
long lived naïve T-cells remains elusive.  T-cell receptor excision circles (TREC) are 
present in thymocytes exiting the thymus and quantification of the most frequent of 
these, the rec-ψJ re-arrangement has been widely used as a measure of recent 
thymic function. However, interpretation of results presented as TREC per cell has 
been criticised on the basis that extra-thymic cellular proliferation impacts on 
peripherally determined TREC numbers.  TREC/ml is now considered to be more 
representative of thymic function than TREC/cell, especially where significant 
cellular proliferation occurs (e.g. during reconstitution following stem cell 
transplantation). Here we describe the validation of a novel variation to the 
established assay, directly quantifying TREC/ml from 300l whole blood. We show 
the assay to be reproducible, robust and stable longitudinally and we show 
equivalence of performance when compared with more standard assays. This assay 
particularly lends itself to the measurement of thymic function in children and where 
monitoring clinical variables is limited by tissue availability. 
Introduction 
An important feature of the adaptive immune response is the broad repertoire of T-
cell receptor (TCR) specificities (1).  TCR diversity is generated through 
rearrangements of TCR alpha (TCR) chain and TCR beta (TCR) chain genes, and 
subsequent random pairing of  and  chain polypeptides (2-4).  The TCR delta 
(TCR) chain locus lies within the TCR chain locus and its excision forms the first 
step in TCR chain gene rearrangement (5). One particularly frequent rearrangement 
occurs between the rec and ψJalpha element recombination sequences. The 
intervening excised DNA is circularised by the formation of a ‘signal joint’ forming a 
DNA episome, termed a signal joint T-cell receptor excision circle (sjTREC).  
Approximately 70% of T-cells emerging from the thymus contain one or two 
sjTRECs (depending on whether one or both TCR loci genes are rearranged) (6). As 
these T-cells mature and proliferate their sjTRECs, which are stable (7) and do not 
divide, are distributed amongst their progeny (8).  
In humans there is no specific phenotypic marker for recent thymic emigrants.  
Although thymic imaging can provide information about thymic capacity (9) it is 
inconvenient, may involve radiation exposure, and does not provide specific 
functional information. In 1998 Douek et al published data suggesting that the 
absolute number of TREC molecules measured per microgram (μg) of DNA derived 
from isolated CD4
+
 and CD8
+
 T cells represented a valid biomarker of thymic 
function (10).  The original semi-quantitative hybridisation assay has since been 
superseded by assays that use real-time quantitative PCR for absolute TREC 
quantification but the underlying principle is that the proportion of peripheral blood 
T-cells containing a TREC provides an approximation of recent thymic function.  
TREC measurements have been presented in a number of different ways. In some 
methods a TREC standard enables the reporting of the absolute number of TREC 
molecules per unit number of cells or TREC molecules per μg of DNA within PBMC 
or T-lymphocytes (11-13). In an alternative approach, TREC DNA has been reported 
relative to genomic DNA within a particular cellular subset (PBMC, T-lymphocytes, 
naïve T-lymhocytes) (14) and yet others have sorted individual T cell subsets and 
measured TREC within that subset (15). The different methods and units used to 
measure TRECs affect the interpretation and comparison of TREC data.  
Additionally, T cell proliferation, T cell death and intra-cellular TREC degradation 
influence the different assays in distinct ways.  In particular, any assay that uses a 
cellular subset as denominator, whether absolute cell number or DNA content, will be 
influenced by cell proliferation within that subset as illustrated by Hazenburg (15). 
For instance if an assay reports TREC per cell, an increase in circulating T- 
lymphocytes as a consequence of peripheral division will artificially dilute the assay 
readout regardless of recent thymic function. As thymic involution occurs a 
proportional decline in peripheral blood TREC numbers occurs and a coincident 
increase in naïve T cell proliferation maintains the size of this T cell compartment 
(16, 17). Memory T cells (CD45RO
+
) contain few if any detectable TREC (18). 
Numerous mathematical models have been described which attempt, using the 
available clinical data, to enhance the interpretation of TREC data in the face of these 
confounding parameters (15, 19, 20). Recently, several authors have concluded that 
measuring TREC per millilitre of blood overcomes the problem induced by cellular 
proliferation in this assay, since the absolute number of TREC molecules, assuming 
there is not significant specific death of TREC containing T cells, remains 
independent of total cell number (21, 22). 
In the current study we describe and evaluate a method which directly quantifies 
TREC from whole blood, using a modification of the currently well described real 
time PCR assay. The value generated is TREC/ml and is therefore measured without 
reference to cellular populations, removing any confounding attributable to cell 
proliferation. Moreover, it is performed using very small quantities of whole blood 
(300ul or less) and removes the necessity for separating PBMC and other T cell 
subsets. The assay is validated and has been tested in a large sample of healthy control 
children and adults.  
 
Materials & Methods 
Samples 
Ethical approval for the study was given by the Newcastle & North Tyneside 
Research Ethics Committee. 9ml blood samples were obtained from healthy 
laboratory controls, individuals attending local blood transfusion donation sessions 
and from healthy children attending the local hospital for simple surgical procedures 
such as hernia repair, circumcision and correction of strabismus. All samples were 
collected in to Vacuette EDTA K3 tubes (Greiner Bio-one, Austria) with informed 
consent from the individual or a parent or guardian.  
 
DNA extraction 
DNA was extracted from 300l of whole blood using the Wizard Genomic DNA 
extraction kit ® (Promega) according to the manufacturer’s instructions and stored at 
4C until use. Sample purity and quantity was determined by spectrophotometry 
(Nanodrop® ND-100).  
 
Isolation of PBMC and CD4
+
 T cells 
PBMC were isolated according to a standard, sucrose density gradient 
(Lymphoprep®) protocol. CD4
+
 T cells were isolated from PBMC with CD4
+
 
positive selection beads (MACS® – Miltenyi Biotec)  using a semi-automated 
positive selection protocol according to the manufacturers instructions yielding 
CD3
+
CD4
+
 T cells with 95-98% purity.  
 
Real time quantitative PCR  
The TREC content of each sample was determined by quantitative real time PCR 
(RQ-PCR) using a standard curve derived from plasmid constructs encoding the 
sjTREC sequence (23). Standards were diluted over the range 10
7
- 10
1
 and a curve 
was run in each experiment together with standard samples, positive and negative 
controls. RQ-PCR was performed using an ABI Prism 7900HT Sequence Detector 
System and data analysed using SDS2.2 software from the manufacturer (Applied 
Biosystems, Warrington, UK). Taqman
TM
 Hydrolysis technology was used in a 25μl 
reaction mixture containing 700nM of each primer CACATCCCTTTCAACCATGCT 
and GCCAGCTGCAGGGTTTAGG, 150nM Taqman hydrolysis probe (6-FAM-
ACACCTCTGGTTTTTGTAAAGGTGCCCACT-TAMRA) and 12.5ul JumpStart
™
 
Taq ReadyMix (SIGMA). Each reaction contained 200ng DNA. Thermal cycling 
conditions were 50C for 2 minutes then 95C for 10minutes then 95C for 15 
seconds and 60C for 1 minute for 40 cycles. Experimental samples were run in 
duplicate and the replicate average value taken as the sample result. Primers and 
probes were all from SIGMA-Aldrich.  
 
Statistics 
All statistical analysis was performed using SPSS
©
 11
th
 edition software. Values for 
TREC/ml were log transformed as described in the text prior to statistical analysis. 
Population distributions were tested with a one sample Kolmogorov-Smirnov test to 
confirm normality. Correlations for normally distributed data were tested for 
significance using Pearson’s correlation coefficient unless otherwise stated. Analysis 
of covariance (ANCOVA) was used to test for differences between groups where 
other covariates were present. Results were considered significant when p < 0.05. 
 
RESULTS 
Direct quantification of TREC per millilitre of whole blood   
We devised a mathematical description for the determination of TREC per millilitre 
of whole blood, where DNA was extracted from a 300μl aliquot of the sample. TREC 
per ml was derived using equation 1. 
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Equation 1– Calculation of TREC per ml of whole blood (WB – whole blood; RQ-
PCR – real time quantitative PCR, No. of TREC is absolute value derived from RQ-
PCR standard curve). 
 
Calculated vales for TREC/ml were log transformed since the size of the error in 
individual results (which had a range of 1.5Log10) was proportional to the size of the 
mean (24). This also allowed statistical analysis to be performed on normally 
distributed data. 
From equation 1, four sources of experimental variability were identified that could 
contribute to measurement error in the assay. Such methodological considerations are 
true for most systems of this nature but infrequently described in the literature. We 
therefore sought to confirm that we could a) reproducibly extract the same quantity of 
DNA from a single donor sample on  multiple occasions; b) that we could 
reproducibly quantify TREC molecules from single donor samples on multiple 
occasions; c) that there was no effect of time from sample donation to sample 
preparation on values obtained and d) that TREC values were independent of total 
white cell count – since granulocytes, B cells and NK cells are all nucleated cells 
present in whole blood. Figure I(A) shows that DNA was reproducibly extracted from 
whole blood samples and Figure I(B) that TREC/ml was reproducibly calculated in 
three of six of these samples. Over a 24 hour period there was no effect of time from 
the sample being drawn to being processed on the quantity of DNA extracted – Figure 
I(C) or the determined TREC value for that sample - Figure I(D). The coefficient of 
variation for the DNA extraction was calculated to be 5.07% from six samples 
extracted 10 times each.  
All white cells (granulocytes, monocytes, B-cells, NK cells & T-cells) in whole blood 
are nucleated and thus in this assay contribute to the total DNA extracted from any 
sample. Since the number of white cells (WC) varies between individuals the total 
WC count may alter the sensitivity of TREC measurements. We therefore assessed 
the relationships between total WC count, lymphocyte count, neutrophil count and 
WBLogTREC/ml. WC count and subset counts were determined in a clinical 
laboratory for a small sample of healthy controls. Samples from patients with 
rheumatological autoimmune diseases who had blood counts available were also 
included. We showed that WBLogTREC/ml was significantly correlated with 
lymphocyte count (sum of T cells (60-80%), B cells (12-20 %), NK cells (10-15%)) (r 
= 0.71; p<0.01). WC count was correlated to a lesser extent, reflecting the lymphocyte 
content of total WC (approximately one third lymphocytes), (r = 0.38; p <0.05). 
Neutrophil count was not correlated with WBLogTREC/ml – Figure II. 
 
Determining assay precision 
The precision of any assay to detect the presence or absence of a quantifiable unit is 
reduced as the limit of detection for the assay is approached. Here, as the number of 
TREC molecules detected per reaction approaches one, the precision of the assay 
declines, reflecting the limit of detection of real time PCR (25). To assess this 
experimentally we quantified TREC from 175 individual samples in duplicate. The 
overall correlation coefficient for the comparison was 0.96; (p<0.01). However, as the 
number of TREC quantified per sample fell below 10, variation in the final result was 
increased. Figure III shows that values to the left of the dashed line (which represents 
the values of WBLogTREC/ml given by samples in which ‘10 or less TREC’ were 
quantified in the real time PCR) are more widely dispersed from the regression line 
than values to the right which represent samples in which ‘11 or more TREC’ were 
measured.  
The coefficient of variation for the real time reaction was calculated by running two 
standard samples of DNA in 25 separate real time experiments and was 1.93% and 
1.49% for each standard sample respectively (data not shown). Thus, the overall 
experimental coefficient of variation from DNA extraction to TREC determination 
(variation in DNA extraction multiplied by variation in RQ-PCR of TREC) was 8.7%, 
range 7.6 - 9.8 %.  
 
Comparison of TREC determination from WB derived DNA with that from PBMC and 
CD4
+
 derived DNA 
For a given quantity of total DNA analysed, selection of TREC-rich cells increases 
the probability of detecting a TREC in a PCR. Thus, in 200ng DNA derived from 
selected T cells the absolute number of TREC will be higher than in 200ng DNA from 
PBMC which in turn will be higher than in 200ng DNA from WB. We have shown 
that our assay becomes less reproducible as TREC/reaction approaches 10 (Figure 
III). However, whereas the use of WB as a template for TREC measurement may 
reduce assay sensitivity, variable T cell recovery may alter the accuracy of analyses 
requiring cellular isolation. We therefore quantified TREC from DNA derived from 
each type of sample in patients known to have values around the limit of detection - 
elderly patients with rheumatoid arthritis taking disease modifying anti-rheumatic 
drugs (DMARDs) (26).  
Samples were initially drawn from ten patients (mean age 60.5yrs (range 48-74yrs)) 
and TREC quantified for each using WB, isolated PBMC and CD4
+
 T cells. Figure 
IV(A) shows that TREC were detected in 8 patients using CD4
+
 T cell DNA, 6 
patients using PBMC DNA and 5 patients using WB DNA. As the frequency of 
TREC per sample increased (as judged by the TREC content of CD4
+ 
T cells) the 
likelihood of detecting TREC using both of the other sample types increased, 
confirming the sensitivity advantage of selecting a TREC-rich subset. However it is 
notable that in two patients where insufficient CD4
+
 T cells were recovered, TREC 
were detected in both using WB DNA and from one using PBMC DNA, emphasising 
the potential cost of cell isolation in terms of accuracy. The detection of TREC in WB 
DNA but not in PBMC DNA from the same individual may also reflect stochastic 
factors as the limit of assay sensitivity is approached.  
We then compared TREC values obtained from PBMC and WB DNA to confirm that 
results from both assays were consistent. We did not compare either with CD4
+ 
T cell 
DNA since the former two assays will additionally include TREC present in CD8
+ 
T 
cells. To increase the sample size for this analysis we isolated DNA from a further 6 
RA patients. TREC were detected in 10/16 using WB and 11/16 using PBMC DNA. 
The correlation coefficient between WB TREC and PBMC TREC values was very 
strong (r = 0.92; r <0.01) confirming equivalence of the data (Figure IVB). 
 
Whole blood TREC per millilitre (WBLogTREC/ml) values are biologically stable 
over time in healthy individuals 
Despite a decline of approximately 1.5 logs over the age span tested, TREC values at 
any one age in normal healthy individuals are still highly variable (13). We therefore 
sought to examine whether biological variation within an individual over time might 
contribute to this variation. Nine healthy male and female volunteers aged between 22 
and 60 had their WBTREC/ml quantified serially over a three month period. We 
found that WBLogTREC/ml remained stable over this period (Figure V). Using the 
standard deviation about the mean as a summary measure (as described by Matthews 
et al (27)) we showed that there was no biological variation above that which could be 
expected from the known inter-assay variation (p = 0.45), confirming that any 
biological variation in healthy individuals occurs at a level not detectable by this 
assay. 
 
WBLogTREC/ml declines with age and varies with gender in healthy individuals 
In healthy individuals thymic function is dependent on age. In a cohort of 221 healthy 
controls ranging in age from new born (cord blood) to 69 we confirmed a decline in 
the number of TREC per ml of approximately 1.5Log. As Zhang et al found (13), 
there is a suggestion of an accelerated decline in thymic function at puberty but it was 
not possible to confirm this observation because our sample number in this age range 
was small (n = 4 for 15-20 years) (Figure VI and Table 1). Moreover, samples at this 
age were all from males. It has previously been shown that males have reduced 
thymic function compared to age-matched females (28). Using the whole blood TREC 
assay we have confirmed this difference and demonstrated that it extends back into 
childhood (Figure VII). The overall age-adjusted mean WBLogTREC/ml for males (n 
= 113) is 4.378 and for females (n = 106) is 4.573 (p = 0.043). Zhang et al did not 
analyse their data on the basis of gender (13) so comparisons cannot be made. 
 
Discussion 
We present here a novel modification to the well established and widely used method 
of measuring thymic function – the ‘TREC Assay’ (10) - which quantifies TREC per 
ml directly from very small volumes of peripheral whole blood.  As discussed earlier, 
we and others have concluded that TREC/ml provides a better estimate of the thymic 
contribution to the peripheral T cell compartment in cross-sectional analyses than 
TREC per cell, the interpretation of which is complicated by the effects of peripheral 
cellular division. Whereas under steady state conditions TREC/ml and TREC per 10
6
 
PBMC (a frequently used unit of TREC per cell) are likely to give comparable results, 
this is not true where there is significant and rapid T cell turnover as, for example, in 
HIV/AIDS after highly active anti-retroviral therapy or following HSCT for 
haematological malignancy or autoimmune disease (20). Such clinical situations are, 
however, of considerable clinical interest.  
The thymus is crucial to reconstitution of the T cell compartment following 
lymphodepletion and also in establishing a normal, diverse T cell repertoire capable 
of mounting an adaptive immune response to neo-antigens, inhibiting auto-reactive 
processes (by the generation of thymus derived regulatory T cells) and detecting early 
malignant expansions (29). Of note, recent evidence suggests that early lymphocyte 
reconstitution following allogeneic or autologous stem cell transplant (SCT) for 
haematological malignancy is positively correlated with a better clinical outcome and 
decreased risk of relapse (30-32). It is known that adults reconstitute poorly in 
comparison with children, that impaired reconstitution is correlated with risk of life 
threatening infection post transplant (33), and that this is due to age related thymic 
involution (34).  Therefore, investigators are now developing strategies which aim to 
restore thymic function and reverse thymic involution in adults (35) and  thymic 
adjuvants such as Keratinocyte Growth Factor, IL-7, Lupron (chemical sex-steroid 
ablative agent) and in vitro expanded T/NK precursor cells are currently being 
evaluated in early clinical trials (for recent reviews see (36, 37)). The impact of these 
agents on thymic function will therefore be evaluated in larger clinical studies in the 
near future.  
We have devised and validated a ‘whole blood TREC assay’ using a large group of 
healthy male and female individuals over a seven decade age range for use in both 
cross sectional and longitudinal studies. Using this assay we have confirmed the 
described 1.5Log fold decline in TREC values with normal aging (13) and the small, 
previously described, increase in thymic function in females when compared with age 
matched males (28). We have shown that, in individual adults, thymic function is 
stable in the short to medium term, irrespective of age, thus demonstrating that this 
assay can be used to monitor thymic function longitudinally and, furthermore, that 
cross sectional analyses can be considered representative of recent thymic function, at 
least in healthy individuals. The assay is cheap, reproducible, stable over time and 
robust to use in longitudinal studies. Our modification to the established TREC assay 
allows thymic function to be measured rapidly from very small volumes of blood and 
thus particularly lends itself to use in clinical settings where limited tissue is available, 
for example in paediatric studies, and/or where longitudinal information is required. 
The lower limit of detection of our assay is higher than that for assays quantifying 
TREC using selected T cell subsets but is directly comparable with assays using 
PBMC derived DNA, with the advantage of significantly lower tissue volume 
requirement and sample processing time. When working at the limit of assay 
sensitivity the probability of TREC detection could be increased by quantifying 
TREC from replicate aliquots of individual samples and adjusting the derived values 
accordingly. 
Our assay cannot distinguish between CD4
+
 and CD8
+
 contributions to the recent 
thymic emigrant subset. However, this limitation is common to most thymic function 
measurements. Sorting peripheral T cell subsets and quantifying TREC within them 
allows both maturation pathways of recent thymic emigrants to be explored (as we 
have previously shown (26)) and, where the total T cell count is known, TREC/ml to 
be calculated. However, this requires large volumes of blood and is less acceptable to 
patients and treating physicians when there are numerous other clinical and 
experimental requirements for peripheral blood. Reflecting this problem, several 
clinical studies have moved to quantify recent thymic emigrants using the phenotype 
CD45RA
+
CD31
+
. Whilst this subset is certainly TREC rich (18, 38) it does not 
always correlate strongly with TREC values and may be capable of self-renewal in 
the absence of thymic output quantified by TREC/ml (39,40) 
Eyrich et al have recently employed a novel approach to the measurement of thymic 
function in the post-SCT context. They showed that two specific time points post 
transplant were of particular clinical interest - Tmin (days until first detectable TREC) 
and Tplateau (days until stable TREC values). These two time points were 
independently regulated by age and grafted stem cell number respectively (41). The 
effects of differing conditioning regimes, graft T cell depletion, use of ex vivo 
thymocyte precursor expansion protocols and thymic adjuvants are all currently being 
investigated in clinical trials to determine their impact on thymic output. Our assay 
will provide a useful clinical tool for the study of these strategies by allowing, for 
example, Tmin and Tplateau to be readily quantified from small clinical samples in large 
clinical cohorts. Time to detection of first TREC may be delayed using our assay in 
such a setting but this disadvantage should be outweighed by the significantly reduced 
sample volume and manipulation required to conduct the assay – a consideration of 
particular relevance in a paediatric context.  Since early reconstitution appears to be 
associated with better prognosis following HSCT in haematological malignancy, our 
assay could also be validated as a prognostic marker.   
 
In summary, our group has previously validated and published an assay that is 
designed specifically for the determination of TREC per cell (14). We now present an 
assay that directly quantifies TREC/ml from whole blood. The combination of the two 
assays, alongside appropriate cell surface labelling contributes a set of tools with 
which thymic reconstitution can be investigated following lymphoablative treatments 
and in the clinical evaluation of thymic adjuvant therapies. 
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Figure VII 
Table I  
 
Age Groups N Minimum Maximum Mean Std.Deviation 
      
0-5 32 4.79 5.79 5.26 0.26 
5.1-10 33 4.56 5.72 5.05 0.26 
10.1-15 15 4.50 5.4 5 0.28 
15.1-20 4 4.38 4.88 4.64 0.20 
20.1-25 14 4.23 4.83 4.53 0.19 
25.1-30 9 4.21 4.79 4.55 0.20 
30.1-35 20 3.90 5.12 4.45 0.26 
35.1-40 16 2.58 4.9 4.12 0.56 
40.1-45 9 3.28 4.74 4.16 0.46 
45.1-50 16 3.53 4.69 4.05 0.30 
50.1-55 23 3.29 4.36 3.84 0.26 
55.1-60 15 2.75 4.69 3.68 0.50 
60.1-65 10 2.80 4.03 3.48 0.40 
65.1-70 4 3.36 4.34 3.84 0.43 
 
Figure Legends 
Figure I 
Determination of assay reproducibility. DNA was extracted from ten 300ul replicate 
aliquots of whole blood from six healthy donors (A). WBTREC/ml was then 
calculated for five of these replicates in three donors (B). To examine the potential 
effect of a delay in sample processing, DNA was extracted from five replicates of a 
single sample at 1 hour, six hours and 24 hours (C). WBLogTREC/ml was then 
quantified in all five aliquots for each time point (D). All plotted values are mean  
SD. 
 
Figure II 
WBLogTREC/ml is positively correlated with lymphocyte count (A) (Pearsons 
correlation coefficient r = 0.67; p<0.01) and weakly with white cell count (r = 0.38; 
p<0.05) (B) but not neutrophil count (p = n.s) (C) when directly quantified from 
whole blood. 
 
Figure III 
Duplicate estimation of the number of TREC molecules per sample was performed for 
175 individuals. Each data point represents the average value obtained from two 
simultaneous PCR’s performed on two (i and ii) occasions for a single donor.  
Overall, the assay was shown to be highly reproducible as evidenced by the regression 
line’s closeness to the diagonal and Pearsons correlation coefficient r = 0.96 (p < 
0.01). However, as the number of TREC determined per reaction approached 10, the 
reproducibility of the assay was less. The vertical dashed line represents the average 
final value of WBLogTREC/ml, calculated according to equation 1, for samples in 
which 10 TREC were measured. Values to the left of the line thus represent samples 
with less than 10 TREC and those to the right those with more than 10 TREC.   
 
Figure IV  
(A) Comparison of TREC values derived from WB DNA (filled bars), PBMC DNA 
(striped bars) and CD4
+
 T cell DNA (white bars) in blood drawn from ten patients 
with rheumatoid arthritis. The age (yrs) of the patients is given below each.  TREC 
values are those derived from the assay standard curve to give raw data values for 
comparison. Where there are no bars for individual subsets TREC were not detected 
in the PCR reaction (or insufficient DNA extracted in the case of the two samples 
where CD4
+ 
samples were tested). Each reaction was performed using 200ng of DNA.  
(B) TREC values derived from the PCR reactions were compared in these ten patients 
plus a further six patients from DNA extracted from PBMC and WB DNA. The 
values derived are strongly correlated (r = 0.92; p < 0.01).  
 
Figure V 
Biological variation in WBLogTREC/ml in HC over 3 months. Nine individuals had 
blood drawn on more than two occasions over a three month period. On each occasion 
DNA was extracted and stored. TREC values were determined for each individual in a 
single real-time experiment. Age and gender for each individual is given.  The 
average value for each individual was taken and plotted against age to check that the 
group was a representative one (Pearson’s r for the correlation with age = -0.904; 
p<0.01). The standard deviation about the mean for each individual was independent 
of age (data not shown). 
 
 Figure VI 
Healthy control samples were divided into 5 year groupings and WBLogTREC/ml 
determined. The mean (thick bar), inter-quartile range (boxes) and 95% confidence 
intervals (whiskers) are plotted. Outliers are plotted as stars (*). Age was negatively 
correlated with WBLogTREC/ml (Pearson’s r = -0.86; p<0.01). 
 
Figure VII 
Gender differences are detectable in WBLogTREC/ml when females (open circles/ 
dashed regression line) are compared with males (closed circles – solid regression 
line) at any age. There is a statistically significant difference between the two groups 
after correcting for age (p = 0.043). The negative correlation with age is maintained in 
each population. (A single sample (male; TREC/ml - 2.58) was removed from this 
analysis because it was an outlier exerting significant influence on the result when 
included). 
 
Table 1 
Mean WBLogTREC/ml for five year cohorts of healthy controls (male and female 
combined) with descriptive statistics for each cohort. Data corresponds to values 
presented in Figure V. 
 
